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Summary
 
Certain types of dendritic cells (DCs) appear in inflammatory lesions of various etiologies,
whereas other DCs, e.g., Langerhans cells (LCs), populate peripheral organs constitutively. Un-
til now, the molecular mechanism behind such differential behavior has not been elucidated.
Here, we show that CD1a
 
1
 
 LC precursors respond selectively and specifically to the CC chemo-
kine macrophage inflammatory protein (MIP)-3
 
a
 
. In contrast, CD14
 
1
 
 precursors of DC and
monocytes are not attracted by MIP-3
 
a
 
. LCs lose the migratory responsiveness to MIP-3
 
a
 
during their maturation, and non-LC DCs do not acquire MIP-3
 
a
 
 sensitivity. The notion that
MIP-3
 
a
 
 may be responsible for selective LC recruitment into the epidermis is further sup-
ported by the following observations: (a) MIP-3
 
a
 
 is expressed by keratinocytes and venular
endothelial cells in clinically normal appearing human skin; (b) LCs express CC chemokine
receptor (CCR)6, the sole MIP-3
 
a
 
 receptor both in situ and in vitro; and (c) non-LC DCs
that are not found in normal epidermis lack CCR6. The mature forms of LCs and non-LC
DCs display comparable sensitivity for MIP-3
 
b
 
, a CCR7 ligand, suggesting that DC subtype–spe-
cific chemokine responses are restricted to the committed precursor stage. Although LC pre-
cursors express primarily CCR6, non-LC DC precursors display a broad chemokine receptor
repertoire. These findings reflect a scenario where the differential expression of chemokine re-
ceptors by two different subpopulations of DCs determines their functional behavior. One
type, the LC, responds to MIP-3
 
a
 
 and enters skin to screen the epidermis constitutively,
whereas the other type, the “inflammatory” DC, migrates in response to a wide array of differ-
ent chemokines and is involved in the amplification and modulation of the inflammatory tissue
response.
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D
 
endritic cells (DCs)
 
1
 
 are bone marrow–derived leuko-
cytes with specialized antigen uptake, processing, and
presentation functions (for reviews, see references 1 and 2).
Under normal, noninflammatory conditions, immature DCs
are found in trace quantities in parenchymatous organs and
contact interfaces between the body and the environment.
The main DC of the epidermis is the Langerhans cell (LC),
a cell type which is anchored to neighboring epithelial cells
via homotypic E-cadherin (E-cad) binding (3, 4). LCs dis-
play CD1a and exhibit typical ultrastructural features (i.e.,
Birbeck granules) that allow their discrimination from
other members of the DC family. Apparently, the still-enig-
matic LC precursor migrates to the skin in the virtual ab-
sence of inflammation-related stimuli. On the other hand,
other types of DCs (e.g., peripheral blood [PB]-DCs) se-
lectively cross activated, but not resting, endothelia (5), or
emerge from transmigrated blood-derived precursors in the
presence of inflammatory stimuli (6). In certain disease
states, inflammation-related DC types may reach the body’s
 
outermost tissues, as evidenced by the appearance of an epi-
dermal non-LC DC population in atopic dermatitis skin (7).
Recent attention has focused on the impact of the
chemokine–chemokine receptor system on DC migration.
Currently, chemokines are subdivided into four subfamilies
according to the position of the first cysteine pair (CXC,
 
1
 
Abbreviations used in this paper:
 
 CB, cord blood; CCR, CC chemokine
receptor; CXCR, CXC chemokine receptor; DC, dendritic cell; DMEC,
dermal microvascular EC; EC, endothelial cell; E-cad, E-cadherin; HPC,
hematopoietic precursor cell; HUVEC, human umbilical vein EC; LC,
Langerhans cell; MCP, monocyte chemotactic protein; mdDC, mono-
cyte-derived DC; MIP, macrophage inflammatory protein; MNC,
mononuclear cell; PB, peripheral blood; PerCP, peridinin chlorophyll
protein; PFA, paraformaldehyde; RANTES, regulated upon activation,
normal T cell expressed and secreted; RPE, R-phycoerythrin; RT, re-
verse transcription; SA-Cy5, Cy5 RPE–conjugated streptavidin; SDF,
stromal cell–derived factor; SLC, secondary lymphoid tissue chemokine. 
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CC), the lack of the second and the fourth cysteine (C), or
the presence of three spacing amino acids in the first cys-
teine tandem (CX
 
3
 
Cs; for reviews, see references 8 and 9).
Until now, five and nine receptors have been identified for
CXC and CC chemokines, respectively. Monocyte-derived
(md)DCs display migratory responsiveness to a broad array
of inflammatory CC chemokines, including monocyte che-
motactic protein (MCP)-1, MCP-2, and MCP-4; regu-
lated upon activation, normal T cell expressed and secreted
(RANTES), macrophage inflammatory protein (MIP)-1
 
a
 
,
MIP-1
 
b
 
, and MIP-5/human CC chemokine 2 (HCC2);
macrophage-derived chemokine; and the CXC chemo-
kines IL-8 and stromal cell–derived factor (SDF)-1
 
a
 
 (10–
16). In correlation to this response profile, mdDCs express
CC chemokine receptor (CCR)1, CCR2, CCR3, and
CCR5, and CXC chemokine receptor (CXCR)1 and
CXCR4 (10, 12, 14, 16). Interestingly, DCs generated in
vitro from CD34
 
1
 
 stem cells, but not mdDCs, express
CCR6 and migrate in response to MIP-3
 
a
 
/liver and acti-
vation-regulated chemokine (LARC [17, 18]). During ter-
minal maturation, mdDCs and CD34
 
1
 
 hematopoietic pre-
cursor cell (HPC)-derived DCs acquire responsiveness to
MIP-3
 
b
 
/EBV-induced molecule 1 ligand chemokine (ELC)
because of the de novo expression of CCR7, a specific re-
ceptor for MIP-3
 
b
 
 and secondary lymphoid tissue chemo-
kine (SLC [10, 13, 18–21]). In keeping with an important
role of CCR7 signaling for the proper function of mature
DCs in vivo is the observation that 
 
plt
 
 mice, which lack ex-
pression of SLC, have reduced numbers of mature DCs in
T cell areas of lymph nodes but, importantly, display an
epidermal LC population that is normal in terms of cell
numbers and distribution (22).
Based on the above considerations, we asked whether sig-
nals governing constitutive DC trafficking are at least partly
different from those regulating the influx of DCs into in-
flammatory sites. To this end, we analyzed the chemokine
responsiveness of in vitro–generated LCs and non-LC DCs,
as well as of their CD1a
 
1
 
 and CD14
 
1
 
 precursors. Further-
more, comparative studies on the chemokine receptor pro-
file of in vitro–generated and ex vivo–isolated LCs, as well as
of inflammation-related DCs (i.e., PB-DCs), and the analysis
of chemokine expression in normal human skin provided in-
sight into the molecular interactions involved in LC homing.
 
Materials and Methods
 
mAbs and Recombinant Growth Factors and Chemokines.
 
FITC-
conjugated mAbs used were anti-CD1a, anti-CCR5, and anti–
B7-2 (PharMingen); anti-CD2 and anti-CD11b (Becton Dickin-
son); and anti-CD3 (Immunotech). PE-conjugated mAbs included
anti-CD14 (Becton Dickinson), anti-CD1a and anti-CXCR4
(PharMingen), and anti-CCR2 and anti-CCR6 (R&D Systems).
The peridinin chlorophyll protein (PerCP)-conjugated anti-CD34
and anti-CD3 mAbs were from Becton Dickinson, and anti-CD1a
CyChrome was from PharMingen. Biotin-conjugated anti-CCR1
was from R&D Systems. The anti–E-cad mAb (Immunotech) was
biotinylated according to standard protocols. The binding of biotin-
ylated mAbs was revealed either by PE- (Becton Dickinson) or
Cy5 R-phycoerythrin (RPE)–conjugated streptavidin (SA-Cy5;
 
Dako). Isotype control mAbs included biotinylated, FITC-, PE-,
or PerCP-labeled mouse IgG1 or IgG2a (Becton Dickinson). Re-
combinant human (rh)GM-CSF and IL-4 were from Novartis
Forschungsinstitut. rhTNF-
 
a
 
 and rhFlt3-ligand (Flt3-L) were ob-
tained from Genzyme and Serotec, respectively. rhMIP-1
 
a
 
, MIP-
3
 
a
 
, MIP-3
 
b
 
, SDF-1
 
a
 
, RANTES, and MCP-1 were obtained
from R&D Systems.
 
Isolation of CD34
 
1
 
 HPCs.
 
Cord blood (CB) was obtained
according to institutional guidelines. CD34
 
1
 
 cells were separated
from CB-MNCs by a positive immunoselection procedure (CD34
MultiSort Kit; Miltenyi Biotec). In brief, CB mononuclear cells
(MNCs [1–2 
 
3
 
 10
 
8
 
]) were incubated with anti-CD34 mAb–coated
paramagnetic microbeads for 30 min at 4
 
8
 
C. After several wash-
ings, bead-bound CD34
 
1
 
 HPCs were isolated on MiniMACS
separation columns using a magnet (MiniMACS; Miltenyi Bio-
tec). CD34
 
1
 
 cells (0.5–1.5 
 
3
 
 10
 
6
 
) were recovered at a purity of
 
.
 
95%, as determined by immunostaining with a PerCP-labeled
anti-CD34 mAb (clone HPCA-2) recognizing a CD34 epitope
distinct from that bound by the mAb used for immunoselec-
tion.
 
In Vitro Generation of DCs from CD34
 
1
 
 HPCs and Isolation of
DC Precursors. 
 
CD34
 
1
 
 HPCs were cultured in RPMI 1640
medium containing 10% FCS (both from GIBCO BRL) supple-
mented with 200 U/ml GM-CSF, 50 U/ml TNF-
 
a
 
, and 50 ng/ml
Flt3-L. CD34
 
1
 
 HPCs were cultured in 75-cm
 
2
 
 tissue culture
flasks (Costar) at a density of 1–2 
 
3
 
 10
 
4
 
/ml. At day 3 or 4, cell
suspensions were split and diluted in fresh RPMI/10% FCS sup-
plemented with GM-CSF and TNF-
 
a
 
. At day 10, cells were col-
lected and resuspended in fresh cytokine-conditioned medium at
a density of 1–2 
 
3
 
 10
 
5
 
/ml, and further cultured until days 12
and/or 14. Where indicated, cells were harvested at day 6 and la-
beled with anti-CD1a–FITC and anti-CD14–PE. CD1a
 
1
 
CD14
 
2
 
cells (24.6
 
 6 
 
2.0% of the total population, mean
 
 6 
 
SEM,
 
 n 
 
5 
 
20)
and CD1a
 
2
 
CD14
 
1
 
 cells (36.1
 
 6 
 
2.2%) were isolated using a
FACStar
 
PLUS™
 
 flow cytometer (Becton Dickinson). The purity of
the sorted cell populations was always 
 
.
 
98%. Sorted cells were
either used in chemotaxis assays, subjected to lysis and mRNA
extraction, or further propagated in the presence of GM-CSF and
TNF-
 
a
 
 until days 12 and/or 14.
 
Isolation and Culture of Epidermal Cells and PB-DCs. 
 
Normal
human skin was obtained from patients undergoing plastic sur-
gery upon informed consent. Keratomed split-thickness skin was
incubated in dispase (50 U/ml; Collaborative Biomedical Prod-
ucts) for 1 h at 37
 
8
 
C, or overnight at 4
 
8
 
C. Thereafter, epidermal
sheets were peeled off and exposed to trypsin/0.05% EDTA
(GIBCO BRL) containing 0.025% DNase 1 (Sigma Chemical
Co.) for 15 min at 37
 
8
 
C, and cell suspensions were prepared by
mechanical agitation. Residual aggregates and cellular debris were
removed by filtering and density gradient centrifugation on Lym-
phoprep (Nycomed Amersham plc). For cell sorting experiments,
epidermal cell suspensions were exposed to anti-CD11b/CD2–
FITC, anti-CD1a–PE, and anti-CD3–PerCP. After several wash-
ings, CD1a
 
1
 
CD2
 
2
 
CD3
 
2
 
CD11b
 
2
 
 LCs and keratinocytes (CD1a
 
2
 
CD2
 
2
 
CD3
 
2
 
CD11b
 
2
 
 cells) were isolated using a FACStar
 
PLUS™
 
flow cytometer. Resulting cell populations were resorted to yield
purities of 
 
.
 
99%. In some experiments, sorted epidermal LCs or
LC-enriched epidermal cell suspensions were cultured for the in-
dicated time periods in GM-CSF (200 U/ml)– and TNF-
 
a
 
 (50
U/ml)–conditioned RPMI 1640/10% FCS. PB-DCs were pre-
pared as described previously (23, 24). In brief, PB-MNCs from
healthy donors were prepared by density gradient centrifugation
on Ficoll-Hypaque (Amersham Pharmacia Biotech) and sub-
jected to counter current elutriation centrifugation (JE-6B elutri- 
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ation system; Beckman Instruments [24]). From the resulting cell
population, T, B, and NK cells, HPCs, monocytes, and basophils
were removed by anti-CD3/CD11b/CD16/CD19/CD34/CD56
immunolabeling and anti–mouse IgG immunomagnetic depletion
(MACS; Miltenyi Biotec). PB-DC–enriched cell populations were
further reacted with anti-CD11c–FITC, anti-CD13–PE, and anti-
CD4–Cy5 mAbs, and CD11c
 
1
 
CD13
 
1
 
CD4
 
1
 
 cells were isolated
on a FACStar
 
PLUS™
 
 flow cytometer. Purified CD11c
 
1
 
 PB-DCs
were seeded at a density of 0.5–1 
 
3
 
 10
 
6
 
/ml in 96-well flat-bot-
tomed microtiter plates (Costar) in RPMI 1640/10% AB serum
supplemented with GM-CSF (1,000 U/ml) and IL-4 (800 U/ml).
 
Isolation and Culture of Dermal Microvascular ECs and Human
Umbilical Vein ECs. 
 
Dermal microvascular ECs (DMECs) were
isolated from human foreskins according to a protocol approved
by the institutional ethics committee. Foreskins were cut into 1-cm
 
2
 
pieces and exposed to dispase (25 U/ml) for 20 min at 37
 
8
 
C.
Cells recovered after gentle teasing of the tissue were resuspended
in low-serum endothelial cell medium (PromoCell) and plated
on dishes coated with fibronectin (1 
 
m
 
g/ml; Endogen, Inc.). For
passaging, cells were recovered from the dishes by trypsin/0.05%
EDTA treatment. Cells were used for further experiments at pas-
sage four. Human umbilical vein ECs (HUVECs) were isolated as
described previously (25) and passaged in IMDM/20% FCS,
streptomycin (100 
 
m
 
g/ml), penicillin (100 U/ml), 
 
l
 
-glutamine
(2 mM; all from GIBCO BRL), EC growth factor (50 
 
m
 
g/ml;
Collaborative Biomedical Products), and heparin (5 U/ml; Sigma
 
Chemical Co.). Activated DMECs and HUVECs were prepared
by exposing the cells for 6 h to 50 ng/ml IFN-
 
g
 
 (Endogen, Inc.).
 
mRNA Extraction and Reverse Transcription PCR Amplification.
 
Primary human cells isolated and cultured as described above
were lysed at a cell density of 4 
 
3
 
 10
 
6
 
/100 
 
m
 
l in Tris/lithium-
dodecylsulfate (LiDS)-containing buffer (100 mM Tris-HCl, 500
mM LiCl, 10 mM EDTA, 1% LiDS, 5 mM dithiothreitol, pH
8.0) for 5 min at 4
 
8
 
C. Poly(A) RNA was isolated using oligo
(dT)
 
25
 
-conjugated Dynabeads (Dynal) according to the manufac-
turer’s recommendations. In brief, 30 
 
m
 
l of the Dynabead oligo
(dT)
 
25
 
 suspension was added to 100 
 
m
 
l cell lysate, and beads were
allowed to hybridize with mRNA poly(A) tails for 5 min at room
temperature. Bead-bound poly(A) RNA was retrieved using a
magnetic particle concentrator (Dynal), and mRNA was eluted
for 3 min at 65
 
8
 
C in H
 
2
 
O. Reverse transcription (RT) of purified
mRNA was performed using the avian myeloblastosis virus
(AMV) first strand cDNA synthesis kit (Boehringer Mannheim).
In brief, eluted mRNA was incubated with 10 mM Tris-HCl, 50
mM KCl, 5 mM MgCl
 
2, 1 mM dNTP, 0.04 A260 U Oligo-
p(dT)15 primer, 50 U RNase inhibitor, and 20 U AMV reverse
transcriptase for 1 h at 428C. Thereafter, the reverse transcriptase
was inactivated by heating the reaction mix to 998C for 5 min.
PCR amplifications were performed in 50 ml reaction buffer (20
mM [NH4]2SO4, 75 mM Tris-HCl, pH 8.8, 0.01% Tween 20,
1.5 mM MgCl2, 0.2 mM of each dNTP, and 2.5 U thermostable
DNA polymerase; all from Advanced Biotechnologies Ltd.), and
Table I. Sequences of Primers Used for PCR Amplification of cDNA Derived from Chemokine Receptor/Chemokine Transcripts, and Sizes
of Products
Transcript Primer sequences (59–39) Product size
bp
CCR1 AAG CTT CAG AGA GAA GCC GGG ATG GAA ACT CC (ref. 46) 1,094
CTC GAG CTG AGT CAG AAC CCA GCA GAG AGT TC (ref. 46)
CCR2 TGG CTG TGT TTG CTT CTG TC 229
TCT CAC TGC CCT TAT GCC TCT
CCR3 AAG CTT CAG GGA GAA GTG AAA TGA CAA CC (ref. 46) 1,084
CTC GAG CAG ACC TAA AAC ACA ATA GAG AGT TCC (ref. 46)
CCR5 TTC CCC TAC AAG AAA CTC TC 328
ATT TCC AAA GTC CCA CTG GG
CCR6 TTT TTC TGC CCA CAA TGA GCG G 1,217
GCA TAC CTG GCC ATA GAC TTT TTT
CCR7 CAT GGA CCT GGG GAA ACC AA 1,174
CTG GGA GAG GTC CCT CTA GT
CXCR4 AAG CTT GGA GAA CCA GCG GTT ACC ATG GAG GGG ATC (ref. 46) 1,084
CTC GAG CAT CTG TGT TAG CTG GAG TGA AAA CTT GAA GAC TC (ref. 46)
MIP-3a CTG TAC CAA GAG TTT GCT CC 254
GCA CAA TAT ATT TCA CCC AAG
MIP-3b TGC CTG TAG TGT TCA CCA 286
CTC ACA CTC ACA CAC ACC CC
b-actin ATC TGG CAC CAC ACC TTC TAC AAT GAG CTG CG* 838
CGT CAT ACT CCT GCT TGC TGA TCC ACA TCT GC*
ref., reference.
*Sequences from Clontech.1758 Selective Role of MIP-3a in LC Migration
20 pM of each primer. Sequences of primer pairs used are given
in Table I. cDNA derived from mRNA of 104 cells was used as
template for individual PCR reactions. Amplified products were
subjected to 2% agarose gel electrophoresis and visualized by
ethidium bromide (Sigma Chemical Co.) staining.
Transwell Insert Chemotaxis Assay.  Chemotaxis assays were
performed as described previously (26). Cells, either directly re-
covered from cultures at the indicated days or FACS® sorted
and recultured overnight in GM-CSF/TNF-a–conditioned me-
dium, were washed and resuspended in migration buffer (HBSS
[GIBCO BRL], 1 mM CaCl2, 0.5 mM MgCl2, 0.1% BSA [Sigma
Chemical Co.)] at a density of 2–3 3 106 cells/ml. 600 ml of
chemokine solution or buffer alone was added to individual wells
of 24-well plates (Costar) on ice. Immediately thereafter, Costar
transwell devices with 5-mm pore size, polyvinylpyrrolidone-free
polycarbonate membranes were inserted into the wells, and 100 ml
cell suspension was layered on top of the membrane. In experi-
ments addressing directional versus random migration, different
concentrations of chemokines were placed above and/or below
the membrane. Cells were allowed to attach to and transmigrate
through the membrane for 2 h at 378C. The fluid phase above
the membrane was then removed, transwell inserts were taken
out of the wells, and membrane-bound cells were stained with
Hemacolor (Merck) for enumeration, or were fixed with 4%
paraformaldehyde (PFA; Fluka AG) for 30 min at 48C, washed,
and processed for confocal laser scanning analysis as described be-
low. Non–membrane-bound, transmigrated cells were recovered
by complete aspiration of the remaining solution in the well.
These samples (i.e., 600 ml) were pooled with the eluates ob-
tained after two washes of the same well with 200 ml HBSS.
Complete removal of cells from the wells was checked by light
microscopy. 10% of the volume (i.e., 100 ml) of individual sam-
ples was subjected to cell enumeration on a FACScan™ (Becton
Dickinson). Using appropriate forward scatter threshold settings,
all cells contained in individual samples were acquired. The num-
ber of cells fulfilling the same forward/side scatter criteria as the
cells before migration was multiplied by 10 to reveal the absolute
number of migrated cells. Cell numbers calculated by this flow
cytometry measurement correlated well with those obtained by
conventional trypan blue exclusion counting using a hemocytome-
ter (data not shown). Cells recovered from the remaining 9/10
of the samples were double/triple-stained with anti-CD1a–
FITC and anti-CD14–PE (cells recovered from 6-d cultures) or
with anti-CD1a–FITC, anti-CD11b–PE, and biotinylated anti–
E-cad/SA-Cy5 (cells recovered from 12- or 14-d cultures).
Confocal Laser Scanning Microscopy.  After PFA fixation, cells
bound to the transwell membrane were stained with 1 mg/ml pro-
pidium iodide in PBS/0.001% saponin (both from Sigma Chemi-
cal Co.) for 1 h at room temperature. Membranes were then cut
out of the transwell inserts, mounted onto slides, and embedded in
VectaShield medium (Vector Laboratories). Slides were examined
using a confocal laser scanning microscope system (LSM 410; Carl
Zeiss, Inc.) equipped with a laser emitting light at 488 nm. Mem-
branes were scanned horizontally by acquiring 32 sections within a
depth of 64 mm. Vertical images were obtained by three-dimen-
sional transformation of data obtained by horizontal sectioning.
Boyden-type Microchamber Chemotaxis Assay.  For comparison,
cell migration was also evaluated using the microchamber chemo-
taxis assay (NeuroProbe) as described previously (27). Chemokines
were diluted as described above, and 30 ml of chemokine solution
or buffer alone was pipetted into individual wells of the 48-well
bottom chamber. Wells were covered with a 5-mm pore size,
polyvinylpyrrolidone-free polycarbonate membrane and a plate
forming the upper compartments. 50 ml of cell suspension (106
cells/ml) was placed into the upper compartment of each well.
Chambers were incubated for 2 h at 378C, filters were harvested,
nonmigrated cells were removed, and the migrated filter-bound
cells were stained with Hemacolor. Chemokine-induced cell mi-
gration was analyzed by computer-assisted counting (Optomax V;
Bestobell Mobrey) of the cells adherent to the bottom side of the
membrane.
Flow Cytometry Analysis.  For two- or three-color immuno-
labeling, cells were washed twice in ice-cold PBS and incubated
in 50 ml PBS containing the appropriate biotin- and/or fluoro-
chrome-labeled mAbs (2.5 mg/ml each) for 30 min on ice. For
the detection of cell-bound biotinylated mAbs, cells were further
exposed to 1 mg/ml SA-PE or SA-Cy5. At least 10,000 cells
were analyzed on a FACScan™ (Becton Dickinson). For the de-
tection of intracellular antigens, cells were subjected to fixation
and permeabilization after surface immunostaining using a kit ac-
cording to the manufacturer’s recommendations (Fix & Perm; An
der Grub Bioresearch).
Actin Polymerization.  HPC-derived cells were harvested on
day 6, washed, and resuspended in migration buffer (1 3 106
cells/ml). After allowing the cells to equilibrate for 15 min at
378C, buffer only or MIP-1a at the indicated final concentration
was added. After the indicated incubation periods, the reaction
was stopped by adding PFA (final concentration 0.1%), and indi-
vidual samples were incubated for 30 min at 48C. Thereafter, cells
were washed and sequentially exposed to anti-CD1a–CyChrome/
anti-CD14–PE and saponin (final concentration 0.1%)/phalloidin–
FITC (final dilution 1:5,000; both from Sigma Chemical Co.),
and subjected to FACS® analysis.
Immunohistochemistry.  Normal human skin was removed
during elective plastic surgery upon informed consent. The skin
samples were snap-frozen in liquid nitrogen–chilled isopentane.
Frozen sections were mounted onto glass slides and fixed for 10
min in acetone at room temperature. Thereafter, the slides were
kept at 2208C for up to 8 wk, until the staining procedure. For
immunostaining, the slides were rehydrated and incubated with
the following primary Abs: rabbit anti–MIP-3a, anti–MIP-3b
(Peprotech), and anti-CCR6 (gift of Joshua Farber, National In-
stitutes of Health, Bethesda, MD [28]); monoclonal mouse anti–
HLA-DR (Biotest), mouse anti-CCR6, anti–MIP-1a, anti–MIP-
1b, and anti-RANTES; and goat anti–SDF-1a and anti–MCP-1
(all from R&D Systems). The bound primary Abs were detected
by sequential incubations with alkaline phosphatase–conjugated
goat anti–rabbit, rabbit anti–mouse, or rabbit anti–goat secondary
Abs and an alkaline phosphatase–anti-alkaline phosphatase stain-
ing kit (Dako), according to the manufacturer’s instructions. To
control the specificity of Ab binding, rabbit, goat, and mouse Ig
and IgG control Abs (Dako) were used at equimolar concentra-
tions. Each immunostaining protocol was performed on skin
from at least three different donors.
Results and Discussion
LCs and Non-LC DC Precursors Respond to Different Sets of
Chemokines.  In a first series of experiments, we investigated
whether chemokines can induce the migration of well-
defined DC types and their precursors in a selective man-
ner. As a model system, we used the cellular progeny of
GM-CSF/TNF-a–stimulated CD341 HPCs. Under these
culture conditions, virtually nonoverlapping CD1a1 and
CD141 cell subsets appear around day 6. Until day 12, they1759 Charbonnier et al.
develop into E-cad1CD11b2CD1a1 LCs and E-cad2
CD11b1CD1a1 non-LC DCs, respectively (29; data not
shown). Chemokines that have been found to induce the
migration of bulk DC populations of various maturational
stages and lineages (i.e., MIP-1a, RANTES, MIP-3a,
MIP-3b, MCP-1, and SDF-1a) were tested. Fig. 1 shows
that, on the basis of their chemokine response pattern,
CD1a1 LCs and CD141 non-LC DC progenitors are func-
tionally diverse cell populations. Most importantly, MIP-3a,
a cytokine with chemotactic activity for CD341 HPC-
derived DCs, but not mdDCs (18), attracted almost ex-
clusively CD1a1 LC precursors (Fig. 1 A). The maximal
MIP-3a–induced response measured for CD141 cells and
for the residual, presumably poorly differentiated, CD142
CD1a2 cell population was at least threefold lower and only
occurred at an MIP-3a concentration 100-fold higher than
that needed to achieve a similar migratory response with
CD1a1 LC precursors (Fig. 1 A). We also confirmed, by a
checkerboard assay, that the CD1a1 LC precursors, as well the
few CD141 cells that were attracted by MIP-3a, migrated in a
directional rather than a random fashion (data not shown).
In addition to being a selective chemoattractant for LC
precursors, MIP-3a was the only chemokine in the panel
tested that induced potent and efficacious migratory re-
sponses of these cells. LC precursors responded only weakly
to SDF-1a and MIP-3b (Fig. 1, C and D), and did not
migrate at all in response to MCP-1, which, in contrast, at-
tracted some CD141 non-LC DC precursors (Fig. 1 B). An-
other chemoattraction profile was observed for the CD142
CD1a2 cell population. As seen previously with HSCs,
these cells were attracted by SDF-1a (Fig. 1 C [30]) and
responded to MCP-1 (Fig. 1 B), but not to MIP-3a or
MIP-3b (Fig. 1, A and D). As shown in Fig. 2 A, MIP-1a
failed to induce migration of day 6 CD341 HPC-derived
DC precursors. The apparent lack of migratory response to
this chemokine was surprising, since day 6 DC precursors
express CCR1 and CCR5, both of which are receptors for
MIP-1a (see below). The transwell migration assay used al-
lows only the analysis of cells that have passed the mem-
brane and detached into the lower chamber, whereas the
cells that remain membrane bound escape detection. To
control for the cells adherent to the lower side of the mem-
brane, we also tested MIP-1a in the Boyden-type chamber
assay, which detects the migrated, membrane-bound cells
only. The direct comparison of the results obtained in these
two migration assays, plus the analysis of the transwell mem-
Figure 1. Chemotactic response of LC and non-LC DC precursors
generated in vitro from CD341 HPCs. CB-derived HPCs were stimu-
lated for 6 d with GM-CSF/TNF-a and then studied in the transwell
chemotaxis assay. MIP-3a (A), MCP-1 (B), SDF-1a (C), or MIP-3b (D)
was placed in individual wells of 24-well plates, transwell devices were in-
serted, and cell suspensions were layered into the transwell inserts. After
2 h at 378C, the cells that transmigrated into the lower compartment were
harvested, stained with anti-CD1a–FITC and anti-CD14–PE, and sub-
jected to FACS® analysis. Results are given as the number of transmi-
grated cells in percentage of the input cell number of individual subpopu-
lations (CD1a1CD142, filled circles; CD141CD1a2, open squares;
CD142CD1a2, open triangles). Mean 6 SEM values obtained in three
different experiments are shown.
Figure 2. MIP-1a and MIP-3a elicit different migratory and/or adhe-
sive responses in CD341 HPC-derived LC and DC precursors. Results
shown in A and B were obtained using the transwell chemotaxis assay and
the 48-well Boyden-type chamber chemotaxis assay, respectively. For both
assays, day 6 LC and/or DC precursors were harvested and tested for their
migratory responses to MIP-1a (filled circles), MIP-3a (open squares), and
MIP-3b (open triangles). Mean percentages (6 SEM) of migrated and de-
tached (A; n 5 3) and migrated, membrane-bound cells (B; n 5 2) are
shown. (C) Representative vertical sections through 5-mm pore size mem-
branes used in the transwell chemotaxis assay. The assays were performed
using the indicated stimuli (MIP-1a at 100 ng/ml, MIP-3a at 1 mg/ml,
and the combination of both), or buffer alone. Membrane-bound cells were
fixed and labeled, and membranes were subjected to confocal laser scanning
microscopy. Broken lines denote the position of the membrane.1760 Selective Role of MIP-3a in LC Migration
branes by confocal microscopy, showed that MIP-1a was
eliciting migratory and/or adhesive responses in CD341
HPC-derived DC precursors that were different from those
induced by MIP-3a (Fig. 2, A and B). In both the
transwell and the Boyden-type assay, the cells that had
been attracted by MIP-1a remained adherent to the mem-
brane (Fig. 2, B and C). In contrast, the cells that had re-
sponded to MIP-3a detached from the lower side of the
membrane in the transwell system (Fig. 2 A) and remained
membrane bound only in the Boyden-type assay (Fig. 2 B).
The proadhesive effect of MIP-1a was pronounced also
when an additional migration-inducing stimulus (e.g.,
MIP-3a) was provided at the same time (Fig. 2 C).
To better characterize the cell populations that respond
to chemokines by adhesion versus transmigration, CD1a1
and CD141 DC precursor subsets were flow sorted on day
6, recultured overnight, and then tested in the transwell
chemotaxis assay. In concordance with our results obtained
with nonsorted DC precursor subsets, MIP-3a induced
vigorous transmigration of sorted CD1a1 LC, but not of
CD141 non-LC DC precursors (Fig. 3 A). The enumera-
tion of cells that migrated but did not detach from the trans-
well membranes revealed that only a minor part of the mi-
grated CD1a1 LC precursors remained membrane bound,
and that only very few CD141 cells adhered to the filters in
response to MIP-3a (Fig. 3 B). The argument that LC,
rather than non-LC DC precursors, are the main MIP-
3a–responsive cell population was further corroborated
in the Boyden-type microchamber chemotaxis assay using
flow-sorted CD1a1 and CD141 DC precursors (data not
shown). In another series of experiments, we used the same
experimental set-up to study MIP-1a–induced migration
of isolated DC precursors. However, unlike their non-
sorted founder population, neither of the two sorted DC
precursor subsets significantly migrated to MIP-1a either
in the transwell or in the Boyden-type microchamber
chemotaxis assay (data not shown). The reason for this dis-
crepancy is not currently understood, but may be due to
desensitization of MIP-1a receptors by chemokines (3, 4,
21) released after the sorting procedure. To still be able to
identify the principal MIP-1a–responsive DC precursor,
we measured MIP-1a–induced actin polymerization, a cel-
lular event occurring early after chemokine receptor trig-
gering (8). As revealed by filamentous (F)-actin and mAb
co-staining experiments performed on nonsorted day 6 DC
progenitor subsets, CD141 non-LC DC precursors and, to
a lesser extent, CD1a2CD142 cells, but no CD1a1 LC pre-
cursors, responded to MIP-1a (Fig. 3 C). In summary, our
cumulative data indicate that MIP-1a (Fig. 2) and
RANTES (not shown), which act on the same set of re-
ceptors, induce non-LC DCs rather than LC precursors to
migrate and to firmly adhere to the substratum. It is possi-
ble that the differential responses of defined DC precursors
to MIP-3a and MIP-1a may be important for the fine-
tuning of migration- versus adhesion-dependent immobili-
zation and, as a result, for the correct localization of the
various types of DCs in the tissues.
LCs and Non-LC DCs Do Not Respond to Chemokines
That Attract Their Precursors, but Both Respond to MIP-3b.
When we compared the effect of chemokines on the mi-
gration of E-cad1CD11b2CD1a1 LCs and of E-cad2
CD11b1CD1a1 non-LC DCs between days 12 and 14, we
observed that neither of the DC types responded to MIP-3a
(Fig. 4 A). In fact, it appears that LCs have completely lost
the MIP-3a reactivity characteristic of their precursor
stage, and that the non-LC DCs did not acquire respon-
siveness to MIP-3a. The finding of a selective but transient
Figure 3. Differential responses of LC and non-LC DC precursors to
MIP-3a and MIP-1a. (A and B) MIP-3a induces migration of LC but
not non-LC DC precursors. Day 6 CD1a+CD142 and CD14+CD1a2
DC precursors were flow sorted, recultured overnight in GM-CSF/
TNF-a–supplemented medium, and thereafter subjected to the transwell
chemotaxis assay. MIP-3a or buffer only was placed in individual wells of
24-well plates, transwell devices were inserted, and cell suspensions were
layered into the transwell inserts. After 2 h at 37°C, migrated cells that
detached into the lower compartment and migrated cells that remained
membrane bound were counted. (A) Mean percentages (6 SD; n 5 2) of
all migrated cells (detached plus membrane bound); (B) mean percentages
(6 SD; n 5 2) of migrated, membrane-bound cells; CD1a+CD142, filled
circles; CD14+CD1a2, open squares. (C) MIP-1a mediates rapid actin po-
lymerization in non-LC DC but not LC precursors. Cells were incubated
for the indicated time periods in the presence or absence of 100 ng/ml
MIP-1a. Cells were fixed with PFA, exposed to anti-CD1a–CyChrome/
anti-CD14–PE, and F-actin was stained by an incubation with saponin/
phalloidin–FITC. The F-actin response (y-axis) of individual cell popula-
tions is given as the ratio of the mean phalloidin-FITC fluorescence in-
tensity in the presence of MIP-1a over the mean phalloidin-FITC fluo-
rescence intensity in its absence. X-axis, elapsed time; CD1a+CD142 LC
precursors, filled circles; CD14+CD1a2 non-LC DC precursors, open
squares; CD1a2CD142 cells, open triangles. Mean 6 SD values obtained
in two different experiments.1761 Charbonnier et al.
involvement of MIP-3a in the migration of defined LC
precursors, but not of monocyte-related DC/DC precur-
sors (Fig. 1 A and Fig. 4 A), together with the observation
of a temporary appearance of MIP-3a–responsive cells in
bulk progenies of cytokine-stimulated CD341 HPCs (18),
suggests that MIP-3a could have a specific role in guiding
LC precursors to their correct anatomical location in vivo.
The refractory state for chemokine-induced migration seen
at day 12 of the cultures (Fig. 4, A–C) lasts for only a short
time period, since at day 14 the LC/DC progeny displayed
pronounced migratory responses to MIP-3b (Fig. 4 C).
Data presented in Fig. 4 C also show that day 14 LCs and
non-LC DCs display quantitatively comparable chemotac-
tic responses to MIP-3b. Thus, DCs show subtype-restricted
chemokine responses at the committed precursor stage only.
LCs Display a Restricted Set of Chemokine Receptors.  To
see (a) whether a correlation exists between the chemokine
expression pattern and the migratory properties of different
types of DCs, and (b) whether our findings are relevant to
the in vivo situation, we analyzed the chemokine receptor
profile of in vitro–generated LCs and freshly isolated epi-
dermal LCs. As shown in Fig. 5 B, epidermal LCs express
mRNAs encoding CCR6, CCR7, and CXCR4, which
are the receptors for MIP-3a, MIP-3b/SLC, and SDF-1,
respectively. In contrast, these cells are virtually devoid of
CCR1, CCR3, and CCR5 transcripts, and express only
limited amounts of CCR2 mRNA. Although a similarly
restricted set of chemokine receptor mRNAs was expressed
by in vitro–generated LCs (Fig. 5 A), other types of imma-
ture DCs and DC precursors, i.e., the progeny of cytokine-
stimulated CD341 HPCs at day 6 (Fig. 5 D), blood DCs
(Fig. 5 E), and monocyte and/or mdDCs (10, 13, 31), ex-
press mRNA for a wide array of different chemokine re-
ceptors, including CCR1, CCR2, CCR3, CCR5, and
CXCR4. These two different patterns were mirrored by
the FACS® data of chemokine receptor expression on the
surface of in vitro–generated LC versus non-LC DC pre-
cursors (Fig. 6 A). CCR6 was the only chemokine receptor
among those studied that was present on the surface of CD1a1
LC precursors (Fig. 6 A). Curiously, CXCR4 was not de-
tected on the surface of these cells, but was found in their
cytoplasm (Fig. 6 A; data not shown). In contrast, CD141
DC precursors expressed several chemokine receptors, in-
cluding CCR1 and CCR5, thus suggesting that the migra-
tory responses to MIP-1a seen in Fig. 2 are indeed con-
fined to this subset.
Immunohistochemistry using both mouse and rabbit Abs
demonstrated strong in situ CCR6 expression by dendritic
epidermal cells of normal human skin (Fig. 6 B; data not
shown). In serial sections, these cells were weakly HLA-
DR1, and thus represent LCs in their nonactivated state
Figure 4. Chemotactic response of LCs and non-LC DCs generated in
vitro from CD341 HPCs. CB-derived HPCs were stimulated for 12 or
14 d with GM-CSF/TNF-a and then studied in the transwell chemotaxis
assay. MIP-3a (A), SDF-1a (B), or MIP-3b (C) was placed in individual
wells of 24-well plates, transwell devices were inserted, and cell suspen-
sions were layered into the transwell inserts. After 2 h at 378C, the cells
that transmigrated into the lower compartment were harvested and
stained with anti-CD1a–FITC, anti-CD11b–PE, and biotinylated anti-
E-cad, followed by SA-Cy5. Results are given as the number of transmi-
grated LCs and non-LC DCs in percentage of the input cell number of
each DC subpopulation (LCs: E-cad1CD11b2CD1a1, filled circles; non-
LC DCs: E-cad2CD11b1CD1a1, open squares) at day 12 (broken lines)
and day 14 (solid lines). Mean 6 SEM values obtained in three different
experiments are shown. Figure 5. RT-PCR analysis of transcripts encoding chemokine recep-
tors in different DC types generated in vitro and purified ex vivo. cDNAs
from the following cell populations were prepared and subjected to PCR:
(A) in vitro–generated LCs, derived from flow-sorted CD1a1 LC precur-
sors of 6-d-old CD341 HPC cultures, analyzed on day 12; (B) epidermal
LCs, freshly isolated from skin and purified by FACS®; (C) flow-sorted
epidermal LCs cultured for 48 h in the presence of GM-CSF/TNF-a;
(D) bulk progeny of GM-CSF/TNF-a–stimulated CD341 HPCs at day
6; (E) freshly isolated CD11c1 PB-DCs. RT, reverse transcription of
mRNA; M, molecular size markers. For primer sequences, see Table I.1762 Selective Role of MIP-3a in LC Migration
(data not shown). In most experiments we also observed
a weak, albeit distinct, granular anti-CCR6 reactivity in
keratinocytes of the Malpighian layer (Fig. 6 B). Our addi-
tional finding of CCR6 mRNA in purified keratinocytes
(data not shown) is indicative of receptor synthesis by these
cells. CCR6 surface expression by a major subset of freshly
isolated HLA-DR1 CD1a1 LCs was also demonstrated by
FACS® (Fig. 6 C). In vitro culture of these LCs under
maturation-promoting conditions resulted in a rapid loss
of anti-CCR6 surface immunoreactivity that even preceded
the maturation-related upregulation of the costimulatory
molecule B7-2 (Fig. 6 C). These data suggest that epidermal
LCs, although CCR61 in their nascent state, downregulate
this receptor during the process of in situ maturation. In
correlation with these results and the maturation-depen-
dent responses of LCs to either MIP-3a or MIP-3b (Figs.
1 and 4), we observed a complete loss of CCR6 mRNA
production with continued synthesis of CCR7 mRNA
during cytokine-mediated maturation of epidermal LCs (Fig.
5 C). Similarly to CCR6 mRNA, CCR2 transcripts disap-
peared during the in vitro maturation of epidermal LCs,
whereas the expression of CXCR4 mRNA remained un-
changed (Fig. 5 C). In conclusion, it appears that immature
LCs ex vivo and those generated in vitro display a similar
and restricted set of chemokine receptors, and that mature
cells no longer produce chemokine receptor mRNAs, with
the notable exception of CCR7 and CXCR4.
In view of data published previously by Zaitseva et al.
(32), the apparent lack of CCR5 mRNA expression by
epidermal LCs appears surprising. Although unlikely, it is
conceivable that LCs express CCR5 mRNA at levels too
low to be detected by our RT-PCR assay. It is important
to note that the LC-purification strategy employed here
strictly excluded CD21 and/or CD31 skin T cells that ex-
Figure 6. Regulation of chemokine receptor expression during LC and non-LC DC develop-
ment. (A) CD1a1 LC precursors express only CCR6, whereas CD141 non-LC DC precursors
display a wide array of chemokine receptors. CD341 HPCs were stimulated for 6 d with GM-CSF/
TNF-a, and cells were exposed simultaneously to CyChrome-labeled anti-CD1a; FITC- or
PE-labeled anti-CD14; and FITC-, PE-, or biotin-conjugated anti-chemokine receptor mAbs.
The binding of biotinylated mAbs was revealed by SA-PE. CD1a1CD142 LC precursors and
CD141CD1a2 non-LC DC precursors were electronically gated and analyzed for their CCR1,
CCR2, CCR5, CCR6, and CXCR4 expression by FACS®. Filled histograms, reactivities of anti-
chemokine receptor mAbs; open histograms, reactivities of label-matched control mAbs. (B) De-
tection of CCR6-expressing cells in normal human epidermis by immunohistochemistry. CCR6
immunoreactivity is seen primarily in basal and suprabasal layers of the epidermis. Strongly immu-
noreactive cells (arrows) have a dendritic configuration (inset), whereas a less pronounced and
granular staining pattern is observed in cells with keratinocyte-like appearance (original magnifica-
tions: 3650; inset, 31,600). (C) Freshly isolated epidermal LCs express CCR6, but rapidly down-
regulate this receptor during in vitro maturation. Freshly prepared (0 h) and cultured (4 h, 20 h)
LC-enriched epidermal cell suspensions were exposed to anti–B7-2–FITC, anti-CCR6–PE, and
anti–HLA-DR–PerCP, and analyzed by FACS®. HLA-DR+ LCs (which homogeneously dis-
played CD1a; data not shown) were electronically gated and analyzed for CCR6 (filled histo-
grams, left) and B7-2 expression (filled histograms, right); open histograms, reactivities of fluoro-
chrome-matched isotype control mAbs.1763 Charbonnier et al.
press CCR5 (data not shown). Moreover, using two differ-
ent mAb clones and RT-PCR, we also failed to detect
CCR5 protein and mRNA expression by in vitro–gener-
ated LCs (Fig. 5 A; data not shown), but could amplify
CCR5-specific transcripts from day 6 cytokine-stimulated
HPCs (Fig. 5 D) and from freshly isolated and cytokine-
stimulated PB-DCs (Fig. 5 E; data not shown).
MIP-3a is the Prime Candidate for Recruiting LC Precursors
into the Epidermis.  To get information about the expres-
sion of chemokines in normal human skin and to correlate
it with the chemokine receptor pattern of LC precursors,
we performed immunohistochemistry and RT-PCR on
frozen skin sections and FACS®-purified skin cells, respec-
tively. Keratinocytes were found to express MIP-3a mRNA
(Fig. 7 I); accordingly, MIP-3a immunoreactivity was seen
in the basal and suprabasal layers of the epidermis (Fig. 7
A). RT-PCR revealed no MIP-3b mRNA in isolated ke-
ratinocytes (Fig. 7 I). Together with our finding of only
sparse and focal epidermal MIP-3b immunoreactivity (not
shown), this suggests that MIP-3b, unlike MIP-3a, is not
constitutively produced in the epidermis. Conversely, we
observed strongly MIP-3b–immunoreactive cells through-
out the dermis (Fig. 7 D). SDF-1a immunoreactivity was
seen in the epidermis but, in contrast to MIP-3a, its ex-
pression was strictly confined to the basal keratinocyte layer
(Fig. 7 C). As shown in Fig. 7 E, normal human epidermis
is devoid of MCP-1 immunoreactivity, an observation that
finds support in a previous publication (33). Also, no MIP-
1a, MIP-1b, or RANTES immunoreactivity was seen in
normal epidermal keratinocytes (data not shown).
Thus, it appears that two chemokines, MIP-3a and
SDF-1a, are produced constitutively by human keratino-
cytes, and therefore could both be involved in LC homing
to the epidermis. Our findings that SDF-1a does not at-
tract LC precursors (Fig. 1 C) and that these cells also fail to
express CXCR4 on their surface (Fig. 6 A) speak against a
role of SDF-1a in LC homing. Since ex vivo–purified LCs
express CCR2 transcripts (Fig. 5 B), one could argue that
this receptor is involved in the attraction of LCs into the
epidermis. This is unlikely because (a) resting keratinocytes
do not express the CCR2 ligand MCP-1 at the protein
level (33; Fig. 7 E), and (b) LC precursors do not express
CCR2 on their surface (Fig. 6 A), and do not migrate in
response to MCP-1 (Fig. 1 B). In this context, it is note-
worthy that mice genetically manipulated to express MCP-1
in the epidermis have close to normal LC numbers while
accumulating dermal DCs and macrophage-like cells (34).
In conclusion, among all the chemokine–chemokine re-
ceptor pairs studied, only MIP-3a–CCR6 fulfills the spatial
and temporal expression, as well as function requirements,
for a ligand–receptor pair responsible for LC homing to the
epidermis. This is evidenced by (a) the constitutive expres-
sion of MIP-3a in normal human epidermis (Fig. 7, A and I);
(b) the selective in vitro chemotactic responses of CD1a1
LC precursors to MIP-3a (Figs. 1 A and 3 A); (c) the ex-
pression of CCR6 by in vitro–generated LC/LC precur-
sors (Figs. 5 A and 6 A), by skin-derived LCs (Figs. 5 B and
6 C), and by LCs in situ (Fig. 6 B); (d) the absence of
CCR6 from non-LC DCs, e.g., PB-DCs (Fig. 5 E), mdDCs
(17), and dermal DCs (data not shown); and (e) the rapid
loss of CCR6 surface expression during LC maturation, as
illustrated by a reverse regulation of CCR6 and B7-2 ex-
pression during LC culture (Fig. 6 C), and the lack of CCR6
expression by cytokine-matured epidermal LCs (Fig. 5 C).
MIP-3a, although absent from spleen and bone marrow,
is also expressed in appendix, thymus, and tonsils as well as
in fetal liver and lung (35–39). Curiously, in tonsils (18),
skin (this study), and perhaps also in the other organs con-
taining epithelial cells, MIP-3a is expressed constitutively
by ectodermal rather than bone marrow–derived cells. Be-
cause keratinocytes produce MIP-3a (Fig. 7, A and I), and
at the same time apparently also express CCR6 (Fig. 6 B;
data not shown), it is possible that, in addition to driving
LC homing, this chemokine plays a previously unrecog-
nized autocrine role in keratinocyte homeostasis.
If MIP-3a is expressed in several different organs, why
do immature LCs appear only in stratified epithelia? It is
conceivable that additional factors, and not MIP-3a expres-
sion alone, determine whether LC precursors can populate
a given organ. A prerequisite for homing into the epider-
mis is the emigration of LC precursors from the circulation,
which, by analogy with other leukocytes, is likely to be
mediated by a cascade of discrete multistep interactions with
ECs (40). Organ-specific differential expression of endo-
thelial adhesion molecules may provide an important addi-
tional source for the selectivity of LC homing into skin.
The multistep adhesion paradigm may also explain how the
lack of expression of leukocyte adhesion molecules, e.g.,
cutaneous lymphocyte-associated antigen (CLA), may be
responsible for the fact that not all CCR6-bearing blood
leukocytes (28) can enter the skin in response to MIP-3a.
We argued above that MIP-3a is ideally positioned to
guide the migration of LC precursors into the epidermis,
but can it also drive their emigration from blood? To do
this, MIP-3a would have to be associated with dermal ECs
and appear on their luminal surface (41, 42). This could be
achieved either by EC binding and transcytosis of kerati-
nocyte-derived MIP-3a, as has been demonstrated previ-
ously for IL-8 and RANTES (42), or by ECs themselves
producing MIP-3a, as was shown for other chemokines
(43). Postcapillary and small venular ECs in normal human
skin display MIP-3a immunoreactivity (Fig. 7 H), and iso-
lated DMECS produce MIP-3a mRNA (Fig. 7 I), show-
ing that, in addition to keratinocytes, dermal ECs also pro-
duce this chemokine under normal conditions. The lack of
MIP-3a mRNA in HUVECs (Fig. 7 I) underlines the site-
specific differences among ECs. Cumulatively, these find-
ings suggest that, in addition to navigating LCs towards the
epidermis, MIP-3a may be the chemokine responsible for
the transendothelial migration of LC precursors.
Additionally, the immunohistochemical studies revealed
MIP-3a and MIP-3b immunoreactivity to be associated
with the ECs of afferent lymphatics (Fig. 7, F and G). This
observation is in line with our previous in situ binding
studies, which demonstrated the presence of saturable, broad
specificity binding sites for CC (MCP-1, MCP-3, RANTES)1764 Selective Role of MIP-3a in LC Migration
but not CXC chemokines on the lymphatic ECs in human
dermis (44). Additionally, SLC immunoreactivity was shown
to be associated with lymphatic vessels (45). The functional
significance of chemokine binding to this microanatomical
location is not yet clear. It is possible that chemokines im-
mobilized on lymphatic ECs facilitate the entry of LCs into
the lymphatics or, alternatively, promote their movement
within the lymphatic channels toward the draining lymph
node. In both cases, the primary role is likely to be played
by CCR7 ligands, since LCs at this stage of their matura-
tion downregulate CCR6 expression.
In this study, we show that LCs display a chemokine re-
sponse pattern that is much narrower than perhaps anticipated.
Thus, the restricted set of chemokine receptors expressed
by constitutively trafficking LCs stands in striking contrast
to the very broad chemokine receptor repertoire of DCs that
Figure 7. Chemokine expres-
sion in normal human skin. (A)
Pronounced MIP-3a immuno-
staining of basal and suprabasal ke-
ratinocytes. (B) Rabbit Ig control
staining (Ig-Co). (C) Only basal
keratinocytes display SDF-1a im-
munoreactivity. (D) No MIP-3b
immunoreactivity is seen in the
epidermis, but scattered dermal cells
are stained (arrow). (E) Neither
the epidermis nor the dermis re-
acts with anti–MCP-1 Abs. (F and
G) ECs lining afferent lymphatics
display MIP-3b and MIP-3a
immunoreactivity (asterisks in F
and G, respectively). (H) MIP-
3a–positive ECs lining a postcap-
illary venule (original magnifica-
tions: A and B, 31,400; C, D, and
E,  3900; F and G, 32,100; H,
33,000). (I) RT-PCR analysis of
MIP-3a and MIP-3b mRNA ex-
pression by keratinocytes (KC);
freshly isolated (LC fresh) as well
as ex vivo–matured epidermal LCs
(LC cult.); fibroblasts (FB);
DMECs; and HUVECs, the latter
two with and without IFN-g
stimulation. RT, reverse transcrip-
tion of mRNA; M, molecular size
markers; PC, positive control for
MIP-3a and MIP-3b mRNA ex-
pression (i.e., reverse-transcribed
mRNA from tonsillar extracts,
reference 14). PCR with b-actin–
specific primers is shown (bottom;
control for the cDNA content of
individual samples).1765 Charbonnier et al.
appear under inflammatory conditions (5, 10, 13, 31; this
study). These findings suggest a scenario where the differ-
ential behavior of two ontogenetically different DC lin-
eages is encoded by their differential expression of chemo-
kine receptors. One cell type, the LC, follows only one
tissue-derived constitutive signal, MIP-3a, and is remark-
ably ignorant to inflammation-related chemokine stimuli. As
a result, it resides in the skin and plays a role in the homeo-
static host defense. Another cell type, exemplified by the
PB-DC, lacks CCR6 but displays a broad repertoire of
chemokine receptors and, consequently, can home to any
inflammatory site where it perpetuates or modulates the in-
flammatory tissue response. It also appears that the ultimate
step in the DC odyssey, i.e., their migration into draining
lymph nodes, follows one pattern common to all DC sub-
types: LCs, non-LC DCs (this study; 18, 45), and mono-
cyte-derived DCs (10, 13, 19, 20) start to express CCR7
and respond to MIP-3b upon receipt of maturation-pro-
moting stimuli. This chemokine, and probably also the al-
ternative CCR7 ligand SLC (22, 45), may guide DCs
into T cell areas of draining lymph nodes.
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